A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2004
12/01/2004	EP1481976A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481975A1 Inhibitors of farnesyl protein transferase
12/01/2004	EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481965A1 Aromatic amino acid derivatives and medicinal compositions
12/01/2004	EP1481688A1 Solidified tissue immunological adjuvant
12/01/2004	EP1481687A1 Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
12/01/2004	EP1481686A1 Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
12/01/2004	EP1481678A1 Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
12/01/2004	EP1481250A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/01/2004	EP1481095A2 Method and nucleic acids for the analysis of colon cell proliferative disorders
12/01/2004	EP1481077A2 Mitotic kinesin inhibitors
12/01/2004	EP1481067A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
12/01/2004	EP1481056A2 Modified human manganese superoxide dismutase and uses therof
12/01/2004	EP1481009A2 Peptides for use in antitumor immunotherapy
12/01/2004	EP1480995A2 Cks1 INHIBITORS
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480984A2 Condensed camptothecins as antitumor agents
12/01/2004	EP1480983A1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
12/01/2004	EP1480982A2 Modified fluorinated nucleoside analogues
12/01/2004	EP1480981A1 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
12/01/2004	EP1480980A2 Syntheses of quinazolinones
12/01/2004	EP1480971A1 Isoquinoline derivatives
12/01/2004	EP1480966A1 Compounds and methods of treating cell proliferative diseases
12/01/2004	EP1480964A1 Inhibiteurs de l'angiogenese
12/01/2004	EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
12/01/2004	EP1480961A1 Glutaminyl based dpiv inhibitors
12/01/2004	EP1480951A1 Synthesis of indole thiazole compounds as ligands for the ah receptor
12/01/2004	EP1480948A1 Semicarbazide derivatives and their use as antithrombotics
12/01/2004	EP1480736A2 Microcapsules having high carotenoid content
12/01/2004	EP1480688A1 N-(5- 4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
12/01/2004	EP1480687A1 Modified phosphocalcic compound, injectable composition containing same
12/01/2004	EP1480679A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
12/01/2004	EP1480676A1 Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents
12/01/2004	EP1480670A2 Cg3842 homologous proteins involved in the regulation of energy homeostasis
12/01/2004	EP1480656A1 Hyaluronic acid mediated adenoviral transduction
12/01/2004	EP1480655A2 Dna demethylase antisense and chemotherapy combination
12/01/2004	EP1480650A1 Novel crystalline forms of the anti-cancer compound zd1839
12/01/2004	EP1480647A1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
12/01/2004	EP1480643A1 Use of epothilones in the treatment of brain diseases associated with proliferative processes
12/01/2004	EP1480636A2 Self emulsifying drug delivery systems for poorly soluble drugs
12/01/2004	EP1480628A1 Use of sodium/hydrogen exchange inhibitors for the treatment of thrombotic and inflammatory diseases
12/01/2004	EP1480621A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
12/01/2004	EP1480598A2 Manipulation of cytokine levels using cd83 gene products
12/01/2004	EP1480548A2 Targeting of a systemically generated immune response to a specific organ or tissue
12/01/2004	EP1480514A2 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
12/01/2004	EP1358180B1 Naphthostyril derivatives and their use as inhibitors of cyclin-dependent kinases
12/01/2004	EP1263761B1 Compounds for pdt
12/01/2004	EP1212428B1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
12/01/2004	EP1183040B1 Therapeutic use of an inhibitor of a hedgehog signalling pathway
12/01/2004	EP1176975A4 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
12/01/2004	EP1119538B1 Derivatives of phenantrene for medicinal use and a process for their preparation
12/01/2004	EP1100778B1 Oxidised sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents
12/01/2004	EP1082422B1 Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
12/01/2004	EP0994697B1 Rapamycin formulations for oral administration
12/01/2004	EP0981365B1 Leptin as an inhibitor of tumor cell proliferation
12/01/2004	EP0977745B1 Thioaryl sulfonamide hydroxamic acid compounds
12/01/2004	EP0845540B1 Monoclonal antibody and antigen relating to human pulmonary adenocarcinoma and immunoassay method with the use of the same
12/01/2004	EP0551401B2 Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
12/01/2004	CN1551914A FAD4, FAD5, FAD5-2 and FAD6, novel fatty acid desaturase family members and uses thereof
12/01/2004	CN1551886A Specific human antibodies for selective cancer therapy
12/01/2004	CN1551885A Cyclic indole and heteroindole derivatives, the production and use thereof as medicaments
12/01/2004	CN1551881A Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
12/01/2004	CN1551878A 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
12/01/2004	CN1551872A Biologically active methylene blue derivatives
12/01/2004	CN1551783A Method for treating multiple myeloma
12/01/2004	CN1551782A Chimeric flavivirus vectors
12/01/2004	CN1551779A Osteogenis oligopeptide as blood-formation stimulation articles
12/01/2004	CN1551772A Inhibition of the growth factor dependency of tumor cells
12/01/2004	CN1551771A Method and composition for treatment of cancer
12/01/2004	CN1551769A Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
12/01/2004	CN1551767A Cancer treatment
12/01/2004	CN1551760A Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
12/01/2004	CN1550550A Oncogene, recombinant protein derived therefrom, and uses thereof
12/01/2004	CN1550231A Method and compositions for administering taxanes orally to human patients
12/01/2004	CN1177934C Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors
12/01/2004	CN1177865C Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
12/01/2004	CN1177860C Cholenic acid amides and pharmaceutical compositions thereof
12/01/2004	CN1177850C Camptothecin analogs and methods of preparation thereof
12/01/2004	CN1177843C Novel chalcones
12/01/2004	CN1177833C Substd. quinazoline derivatives
12/01/2004	CN1177832C Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
12/01/2004	CN1177831C New benzimidazolone-benzoxazolone-, or benzothiazoloe derivatives as ion channel modulating agents
12/01/2004	CN1177830C Benzoheterocycles and their use as MEK inhibitors
12/01/2004	CN1177829C Substituted sulphonyl cyanamides, method for producing same and their use as medicament
12/01/2004	CN1177828C Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
12/01/2004	CN1177821C Matrix metalloprotease inhibitors
12/01/2004	CN1177615C Arteriovenous and venous graft treatment methods and compsns.
12/01/2004	CN1177610C Pharmaceutical composition for immunomodulation based on peptides and adjuvants
12/01/2004	CN1177594C Formulation for use in prevention of pathogen induced diseases including HIV and HSV
12/01/2004	CN1177593C Fructan containing compsn. for prevention and treatment of colon cancer
12/01/2004	CN1177591C Medicaments that contain xenogenic oligo-or/and polyribonucleotides
12/01/2004	CN1177590C Cyclophosphamide coated tablets
12/01/2004	CN1177583C Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
11/2004
11/30/2004	US6825360 Bicyclic aromatic compounds
11/30/2004	US6825350 Administering dosage of immunology response moderator
11/30/2004	US6825349 Purine derivatives for treatment of gastrointestinal disorders, immunological disorders, neurological disorders
11/30/2004	US6825343 1,3-dipolar cycloadditions to polypyrrolic macrocycles
11/30/2004	US6825326 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds
11/30/2004	US6825317 Histone deacetylase inhibitor, a major histocompatibility complex class-i molecule expression-promoting agent and anticancer agents
11/30/2004	US6825229 Administering protein kinase c activators such as macrocyclic lactones (i.e. bryostatin class and neristatin class)

1 ... 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 ... 2211